Octapharma operates as a privately held, independent global biopharmaceutical enterprise rather than a subsidiary owned by a larger corporate parent. Founded and managed by the Haenggi family, the organization functions autonomously with its own dedicated executive leadership structure, specialized research laboratories, and worldwide manufacturing plants dedicated to producing human protein products derived from plasma and recombinant technologies.